Diagnostic Challenges in a Young Man with a Suspected Mast Cell Disorder, Dysplastic Bone Marrow Morphology, and a ZRSR2 Mutation

Riccardo Dondolin(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Riccardo Moia(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Nawar Maher(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Gianluca Gaïdano(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Andrea Patriarca(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Annalisa Andorno(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Mohammad Reshad Nawabi(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Sayed Masoud Sayedi(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”)
Hematology Reports
November 25, 2025
10.3390/hematolrep17060064
Cited by 0

Related Papers

Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k
The coding genome of splenic marginal zone lymphoma: activation of <i>NOTCH2</i> and other pathways regulating marginal zone development
|The Journal of Experimental Medicine|2012|378
Clinical heterogeneity and predictors of outcome in primary autoimmune hemolytic anemia: a GIMEMA study of 308 patients
|Blood|2014|373
Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia
|Blood|2015|216
Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance With Bortezomib-Thalidomide Compared With Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: Updated Follow-Up and Improved Survival
|Journal of Clinical Oncology|2014|210